Table 3.

Treatment efficacy of bevacizumab-containing regimens

Response	Overall	MSS (n=134)	MSI (n=6)	p-value	Left side (n=106)	Right side (n=34)	p-value
Complete response
Partial response	72	68	4		55	17
Stable disease	44	43	1		35	9
Progressive disease	25	23	1		16	8
Response rate	51.4%	50.8%	66.7%	0.681	51.9%	50.0%	0.848
Disease control rate	82.9%	82.8%	95.8%	0.975	84.9%	76.5%	0.297

MSS: microsatellite stable, MSI: microsatellite instability